VIR - Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? | Benzinga
On Wednesday, Vir Biotechnology Inc (NASDAQ:VIR) announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart and elebsiran for chronic hepatitis delta.
Preliminary data from the Phase 2 trial show that treatment with tobevibart alone or combined with elebsiran was generally well tolerated.
Participants achieved high virologic response rates at weeks 12 and 24, ...